Circulating SFRP5 levels are elevated in drug‐naïve recently diagnosed type 2 diabetic patients as compared with prediabetic subjects and controls

Abstract

Circulating SFRP5 levels were independently associated with T2D as compared with prediabetes and normal glucose tolerance state.

Sfrp5 associates with beta‐cell function in humans

“…The use of dynamic measures of beta-cell function after ingestion of glucose in the OGTT might explain that we found an inverse association between circulating Sfrp5 and beta-cell function, whereas two human studies using HOMA-B as marker of fasting beta-cell function failed to find any significant association between these parameters (r = 0Á14 to À0Á05, P > 0Á05) [21,22]. This inverse correlation may appear surprising given that individuals with IGT/T2D had both reduced Sfrp5 levels and decreased C-peptide-derived beta-cell function compared to individuals with NGT.…”

“…Another study found that Sfrp5 overexpression in mice increased the ratio proinsulin/C-peptide which suggests an unfavourable role in the normal insulin maturation process [25]. Two studies in humans failed to observe any association between serum Sfrp5 and homoeostasis model assessment of beta-cell function (HOMA-B), a surrogate marker of beta-cell function [21,22], but data based on dynamic (e.g. oral glucose tolerance test (OGTT)-based) measures of insulin secretion and beta-cell function are currently lacking.…”

Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study

“…Additionally, two studies also reported lower Sfrp5 levels in patients with type 2 diabetes compared to individuals with normal glucose tolerance [11, 12]. However, it is in contrast to two human studies which found a positive [10] and no relationship [14] to HOMA-IR or higher Sfrp5 levels in patients with type 2 diabetes compared to prediabetic individuals, although no difference to the group with normal glucose tolerance was observed [14]. Different laboratory methods cannot explain the observed differences because this study and the aforementioned studies [10–15] used the same method to measure circulating SFRP5 (purchased from Cloud-Clone, previously distributed by USCN).…”

“…However, the previous studies were based on small sample sizes, they were not population-based and differed in their adjustment for potential confounders. In particular the study with the opposing result of higher Sfrp5 levels in patients with type 2 diabetes was based on highly selected individuals with optimal glycaemic control (median HbA1c 5.8%) who cannot be considered representative for people with type 2 diabetes in the general population [14]. …”

“…Cross-sectional studies including people with and/or without type 2 diabetes found that circulating SFRP5 showed a positive [10], an inverse [11–13] or no association [14] with insulin resistance. In two hospital-based studies serum SFRP5 was inversely associated with the metabolic syndrome and the severity of coronary artery disease [13, 15].…”